Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S et al.: Cancer Statistics, 2000. CA Cancer J. CBIl. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• LEE JS, SCOTT C, KOMAKI R et al.: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. _J. CBIl. Oncol. (1996) 14:1055–1064.
   PubMedGoogle Scholar
• DILLMAN RO, SEAGREN SL, PROPERTKJ etal.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl. j Med (1990) 323:940–945.
   Google Scholar
• SAUSE W, KOLESAR E TAYLOR S et al.:Five-year results: Phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992. Proc. Am. Soc. CBIl. arca (1998) 17:453a. Abstract 1743.
   Google Scholar
• SAUSE WT, SCOTT C, TAYLOR S et al.:Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer. j Nati Cancer Inst. (1995) 87:198–205.
   PubMed Web of Science ®Google Scholar
• LE CHEVALIER T, ARRIAGADA R, QUOIX E etal.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. j Natl. Cancer Inst. (1991) 83:417–423.
   Google Scholar
• JEREMIC B, SHIBAMOTO Y, ACIMOVIC L et al.: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. j Clin. arca (1995) 13:452–458.
   PubMed Web of Science ®Google Scholar
• JEREMIC B, SHIBAMOTO Y, ACIMOVIC L et al.: Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/ etoposide for stage III non-small cell lung cancer, a randomized study. j CBIl. arca (1996) 14:1065–1070.
   Google Scholar
• KOMAKI R, SCOTT C, LEE JS et al.: Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06. Am. J CBI]. arca (1997) 20:435–440.
   Google Scholar
• SCHAAKE-KONING C, VAN DEN BOGAERT W, DALESIO 0 et al.:Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl. J Med. (1992) 20:326(8):524–530.
   Google Scholar
• BALL D, BISHOP J, SMITH J et al. A randomised Phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother. Oncol. (1999) 52(2):129–136.
   PubMedGoogle Scholar
• EDELMAN MJ, GANDARA DR, ROACH M III et al.: Multimodality therapy in stage III non-small cell lung cancer. Ann. Thorac. Surg. (1996) 61:1564–1572.
   Google Scholar
• GRECO FA, HAINSWORTH JD: Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology (1997) 11:27–36.
   PubMedGoogle Scholar
• DILLMAN RO, HERNDON J, SEAGREN SL et al.: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. I Nati Cancer Inst. (1996) 88:1210–1215.
   PubMed Web of Science ®Google Scholar
• SAUSE W, KOLESAR P, TAYLOR S et al.:Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest (2000) 117:358–364.
   PubMed Web of Science ®Google Scholar
• FURUSE K, FUKUOKA M, KAWAHARA M et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J CBI]. Oncol. (1999) 17:2692–2699.
   PubMed Web of Science ®Google Scholar
• CURRAN W, SCOTT C, LANGER C et al.: Phase III comparison of sequential vs. concurrent chemo-radiation for pts with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer (2000) 29 (Suppl. 1):93 Abstract 303.
   Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, DONEHOWER RC: Paclitaxel (Taxol). N Engl. I Med. (1995) 332:1004–1014.
   PubMed Web of Science ®Google Scholar
• PICCART MJ, GORE M, TEN BOKKEL HUININK W et al.: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. j Nati Cancer Inst. (1995) 87:676–681.
   PubMed Web of Science ®Google Scholar
• BELANI CP, AISNER J, HIPONIA D et al.: Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Sem:in arca (1995) 22(4 Suppl. 9):7–12.
   Google Scholar
• CERNY T, KAPLAN S, PAVLIDIS N et al.: Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br .j Cancer (1994) 70:384–387.
   PubMed Web of Science ®Google Scholar
• MANFREDI JJ, PARNESS J, HORWITZ SB: Taxol binds to cellular microbutules. Cell Biol. (1982) 94:688–696.
   PubMed Web of Science ®Google Scholar
• PARNESS J, HORWITZ SB: Taxol binds to polymerized tubulin in vitro. j Cell Biol. (1981) 91:479–487.
   PubMed Web of Science ®Google Scholar
• GUERITTE-VOEGELEIN E GUENARD D, LAVELLE F et al.: Relationships between the structure of Taxol analogues and their antimitotic activity. j Med. Chem. (1991) 34:992–998.
   PubMedGoogle Scholar
• SCHIFF PB, HORWITZ SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Nati Acad. Sci. USA. (1980) 77:1561–1565.
   PubMed Web of Science ®Google Scholar
• MILROSS CG, MASON KA, HUNTER NR et al.: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. Nati Cancer Inst. (1996) 88:1308–1314.
   PubMed Web of Science ®Google Scholar
• MILAS L, HUNTER NR, MASON KA et al.: Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. (1995) 55:3564–3568.
   PubMed Web of Science ®Google Scholar
• CHANG AY, KIM K, GLICK J etal.: PhaseII study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. I Natl. Cancer Inst. (1993) 85:388–394.
   Google Scholar
• MURPHY WK, FOSSELLA FV, WINN RJ et al.: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. j Natl. Cancer Inst. (1993) 85:384–388.
   PubMed Web of Science ®Google Scholar
• CHOY H, AKERLEY W, SAFRAN H et al.: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. CMI. arca (1994) 12:2682–2686.
   Google Scholar
• CHOY H, SAFRAN H, AKERLEY W et al.: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res. (1998) 4:1931–1936.
   PubMed Web of Science ®Google Scholar
• CHOY H, AKERLEY W SAFRAN H et al.: Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. I CMI. arca (1998) 16:3316–3322.
   Google Scholar
• CHOY H, DEVORE RF 3RD, HANDE KR et al.: A Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int. I Radiat. arca Biol. Phys. (2000) 47:931–937.
   Google Scholar
• CHOY H, LAPORTE K, KNILL-SELBY E etal.: Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semirr. Radiat. arca (1999) 9(2 Suppl. 1):90–96.
   Google Scholar
• SOCINSKI MA, ROSENMAN JG, SCHELL MJ et al.: Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer (2000) 89:534–542.
   PubMedGoogle Scholar
• SOCINSKI MA, HALLE J, SCHELL MJ etal.: Induction (I) and concurrent (C) carboplatin/paclitaxel (C/P) with dose-escalated thoracic conformal radiotherapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC): a Phase I/II trial. Proc. Am. Soc. CMI. arca (2000) 19:496a. Abstract 1940.
   Google Scholar
• LAUD, LEIGH B, GANDARA D et al.: Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatinipaclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium Phase II Trial. j Clin. arca (2001) 19:442–447.
   PubMedGoogle Scholar
• ORAL EN, BAVBEK SE, KIZIR A et al.: Preliminary results of weekly paclitaxel (P) and continuous hyperfractionated accelerated radiotherapy (CHART) in locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. CMI. arca (1999) 18:480a. Abstract 1852.
   Google Scholar
• LAU DH, RYU JK, GANDARA DR et al.: Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Strain arca (1997) 24(4 Suppl. 12):5106–5109.
   Google Scholar
• CHEN Y, PANDYA K, OKUNIEFF P et al.: Pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach based on pre-clinical research of human lung cancer cells. Lung Cancer (2000) 29\(Suppl. 1):125. Abstract 415.
   Google Scholar
• KIRKBRIDE P, GELMON K, EISENHAUER E: Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian Experience. Sem:in. Radiat. arca (1999) 9\(Suppl. 1):102–107.
   Google Scholar
• RATHMANN J, RIGAS JR, LEOPOLD KA: Daily paclitaxel and thoracic radiation therapy for stagenon-small cell lungcancer. Sem:in arca (1999) 26\(Suppl. 2):72.
   Google Scholar
• BELANI CP: Combined modality therapy for unresectable stage III non-small cell lung cancer. Chest (2000) 117:127S–132S.
   Google Scholar
• AKERLEY W, HERNDON J, TURRISI A et al.: Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis of a Phase II trial by Cancer and Leukemia Group B. Proc. Am. Soc. Clin. arca (2000) 19:490a. Abstract 1915.
   Google Scholar
• LANGER C, MOVSAS B, SCHOL J et al.: Induction paclitaxel and carboplatin (CBDCA) followed by concurrent chemo-radiation (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center 94–001. Semin arca (1999) 26\(Suppl. 18):26.
   Google Scholar
• GRECO FA, STROUP SL, GRAY JR et al.: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. I Clin. arca (1996) 14:1642–1648.
   Google Scholar
• VOKES EE, LEOPOLD KA, HERNDON JE et al.: CALGB study 9431: a randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NS CLC) . Lung Cancer (2000) 29 (Suppl. 1):49. Abstract 158.
   Google Scholar
• MATTSON K, ISOKANGAS OP, HALME M et al.: Paxlitaxel and carboplatin followed by concomitant paclitaxel, cisplatin, and radiotherapy for inoperable stage III non-small cell lung cancer. Semil. arca (1999) 26\(Suppl. 2):72.
   Google Scholar
• ROYCHOWDHURY DF, REDMOND K, DESAI P et al.: A Phase II trial of amifostine with paclitaxel, carboplatin and concurrent radiation therapy for unresectable non-small cell lung cancer. Proc. Am. Soc. Chia. Oncol. (1999) 18:522a. Abstract 2011.
   Google Scholar
• BUNN PA JR, VOKES EE, LANGER CJ et al.: An update on North American randomized studies in non-small cell lung cancer. Semin. Oncol. (1998) 25(4 Suppl. 9):2–10.
   Google Scholar
• CHOY H: Combining taxanes with radiation for solid tumors. Int. j Cancer (2000) 90:113–127.
   PubMedGoogle Scholar
• VOKES EE, LEOPOLD KA, HERNODON JE II et al: A CALGB randomized Phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in stage IIIB non-small cell lung cancer (NSCLC): feasibility data (CALGB study #9431). Proc. Am. Soc. Chu. Oncol. (1997) 16:455a. Abstract 1636.
   Google Scholar
• SAUSE WT, SCOTT C, KOMAKI R et al: Combined chemotherapy radiation therapy treatment in unresectable non-small cell lung cancer Radiation Therapy Oncology Group (RTOG) experience. Lung Cancer (2000) 29\(Suppl. 2):58–59.
   Google Scholar
• BELANI CP: Incorporation of paclitaxel and carboplatin in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Oncol. (1999) 26(1 Suppl. 2):44–54.
   Google Scholar
• CHOY H: Weekly paclitaxel-based combined modality therapy in stage III non-small cell lung cancer: the sequential trial. Cancer. (In Press).
   Google Scholar
• BISSERY MC, NOHYNEK G, SANDERINK GJ etal.: Docetaxel (Taxotere): a review of preclinical and clinical experience. part I: preclinical experience. Anticancer Drugs (1995) 6:339–355.
   PubMed Web of Science ®Google Scholar
• LAVELLE E BISSERY MC, COMBEAU C et al.: Preclinical evaluation of docetaxel (Taxotere). Smith. Oncol. (1995) 22:3–16.
   Web of Science ®Google Scholar
• RIOU JF, NAUDIN A, LAVELLE F: Effects of Taxotere on murine and human tumour cell lines. Biochem. Biophys. Res. Commun. (1992) 187:164–170.
   PubMed Web of Science ®Google Scholar
• HALDAR S, BASU A, CROCE CM: Bc12 is the guardian of microtubule integrity. Cancer Res. (1997) 57:229–233.
   PubMed Web of Science ®Google Scholar
• VANHOEFER U, CAO S, HARSTRICK A et al.: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein. Ann. Oncol (1997) 8:1221–1228.
   PubMed Web of Science ®Google Scholar
• BURRIS H, ECKARDT J, FIELDS S et al: Phase II trials of taxotere in patients with non-small-cell lung cancer. Proc. Am. Soc. Chu. Oncol. (1993) 12:335. Abstract 1116.
   Google Scholar
• FOSSELLA FV, LEE JS, MURPHY WK et al.: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. Chu. Oncol. (1994) 12:1238–1244.
   PubMed Web of Science ®Google Scholar
• FRANCIS PA, RIGAS JR, KRIS MG et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Chu. Oncol. (1994) 12:1232–1237.
   PubMed Web of Science ®Google Scholar
• ORNSTEIN DL, RIGAS JR: Taxotere: clinical trials in non-small cell lung cancer. Oncologist (1998) 3:86–93.
   PubMedGoogle Scholar
• GANDARA DR, VOKES E, GREEN M et al.: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a Phase II multicenter trial. j Chu. Oncol. (2000) 18:131–135.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. I Chu. Oncol (2000) 18(10):2095–2103.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN etal. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Chu. Oncol (2000) 18(12):2354–2362.
   Google Scholar
• KOUKOURAKIS MI, BAHLITZANAKIS N, FROUDARAKIS M et al: Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br .j Cancer (1999) 80:1792–1796.
   PubMed Web of Science ®Google Scholar
• AAMDAL S, LAU WANG G, OWRE K etal.: A Phase I/II study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer (2000) 29\(Suppl. 1):100. Abstract 327.
   Google Scholar
• CHOY H, DEVORE RF, PORTER LL et al.: Phase I trial of outpatient weekly docetaxel (DTX) Carboplatin (CBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Proc. Am. Soc. Chu. Oncol. (1999) 18:475a. Abstract 1833.
   Google Scholar
• MURAKAMI H, KUBOTA K, OHE Y et al.: Phase I study of weekly docetaxel (DTX) and carboplaitn (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC). Lung Cancer (2000) 29\(Suppl. 1):111. Abstract 367.
   Google Scholar
• SEGAWA Y, UEOKA H, KIURA K et al: Aphase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Proc. Am. Soc. Chu. Oncol. (2000) 19:508a. Abstract 1988.
   Google Scholar
• NYMAN J, MERCKE C: Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer. Lung Cancer (2000) 29\(Suppl. 1):98. Abstract 323.
   Google Scholar
• ALBAIN K, RUSCH V, CROWLEY J etal.:Long-term survival after concurrent cisplatinktoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stage IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proc. Am. Soc. Chu. Oncol (1999) 18:467a. Abstract 1801.
   Google Scholar
• CHOI NC, CAREY RW, DALY W etal.:Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. I Chu. Oncol. (1997) 15:712–722.
   Google Scholar
• EBERHARDT W WILKE H, STAMATIS G etal.: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a Phase II trial. j Chu. Oncol. (1998) 16:622–634.
   Google Scholar
• THOMAS M, RUBE C, SEMIK M etal.: Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small cell lung cancer. I Chu. Oncol (1999) 17:1185–1193.
   Google Scholar
• ALGAZY KM, MACHTAY M, FRIEDBERG JS et al.: Neoadjuvant chemoradiotherapy prior to surgery for stage IIIA Non-small cell lung carcinoma (NSCLC): a nonrandomized comparison of carboplatin/paclitaxel to etoposide/ cisplatin. Proc. Am. Soc. Clin. amyl (1999) 18:494a. Abstract 1906.
   Google Scholar
• MACHTAY M, HAHN SM, ROBNETT TJ et al.: Neoadjuvant paclitaxel-carboplatin plus irradiation (XRT) improves resectability and local-regional control over neoadjuvant paclitaxel alone for stage IIIA non-small cell lung carcinoma (NSCLC). Proc. Am. Soc. Clin. Oricol (2000) 19:509a. Abstract 1991.
   Google Scholar
• GRESKOVICH JF, ADELSTEIN DJ, RICE TW etal.: Accelerated fractionation radiation (AFR), concurrent paclitaxel/ cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. Proc. Am. Soc. Clin. Oricol (2000) 19:499a. Abstract 1954.
   Google Scholar
• GEORGIADIS M, BROWN D, GALLOWAY M et al.: Induction chest radiotherapy (RT) with weekly paclitaxel and carboplatin in marginally resectable non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oricol (1999) 18:505a. Abstract 1948.
   Google Scholar
• FERRANTE K, WINOGRAD B, CANETTA R: Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol (1999) 43(Suppl): S61–S68.
   Google Scholar
• MENENDEZ A, LAIDLAW J, RAVENTOS-SUAREZ C etal.: In vitro characterization of BMS-184476, a novel taxane with promising preclinical activity. Proc. Am. Assoc. Cancer Res. (2000) 41:554. Abstract 3529.
   Google Scholar
• HIGHELY M, SESSA C, HUGHES A etal.: Phase I and pharmacokinetic (PK)study of BMS-184476, a new taxanes analog, given weekly in patients with advanced malignancies. Proc. Am. Soc. Clin. amyl (1999) 18:168a. Abstract 644.
   Google Scholar
• HIDALGO M, AYLESWORTH C, FERRANTE K et al.: Phase land pharmacokinetic (PK) study of BMS-184476, a potent and soluble taxane analog, as a 1-hour infusion every 3 weeks. Proc. Am. Soc. Clin. Oricol (1999) 18:168a. Abstract 645).
   Google Scholar
• Set al.: Phase I clinical and pharmacokinetic study of the taxanes analog BMS-184476 administered as a 1-hour iv infusion in combination with carboplatin every 21 days. Proc. Am. Assoc. Cancer. Res. (2000) 41:608. Abstract 3871.
   Google Scholar
• YANG LX, WANG HJ, HOLTON RA: In vitro efficacy of a novel chemoradiopotentiator - taxoltere metro. Int. I Radiat. Oricol. Biol. Phys. (2000) 46:159–163.
   PubMedGoogle Scholar
• WOLFF AC, BAKER SD, BOWLING MK et al.: Phase I study of Taxoprexin Dha-paclitaxel (Txp), a novel taxanes with unique preclinical activity, pharmacology, and toxicity profile. Proc. Am. Soc. Clin. Oricol (2000) 19:236a. Abstract 921E.
   Google Scholar
• ROSE WC, LEE FYF, GOLIK J et al: Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivate. Cancer Chemother Pharmacol (2000) 46:246–250.
   PubMedGoogle Scholar
• BUNN PA, SORIANO A, JOHNSON G etal.: New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest (2000) 117:163S–168S.
   Google Scholar
• ZHANG L, HUNG MC: Sensitization of HER-2/neu-over-expressing non-small cell lung cancer cell to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oricogerie (1996) 12:571–576.
   Google Scholar
• KRONING R, JONES JA, HOM DK et al.: Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br. J. Cancer (1995) 72:615–619.
   PubMedGoogle Scholar
• PIETRAS RJ, POEN JC, GALLARDO D et al.: Monoclonal antibody to HER-2/neu receptor modulates repair of radiation induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. (1999) 59:1347–1355.
   PubMed Web of Science ®Google Scholar
• MONZO M, ROSELL R, SANCHEZ JJ et al.: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. I Clin. amyl (1999) 17:1786–1793.
   Google Scholar
• ROSELL R, MONZO M, SANCHEZ J et al.: Beta-tubulin mutations in circulating extracellular DNA of non-small cell lung cancer (NSCLC) patients (pts). Proc. Am. Soc. OM. Oricol (2000) 19:485a. Abstract 1897.
   Google Scholar
• SISTERMANNS J, HOFFMANNS H: Phase II study of docetaxel with simultaneous radiochemotherapy in patients with locally advanced non-resectable non-small cell lung cancer (NSCLC) - preliminary results. Proc. Ain. Soc. OM. Oricol (1999) 18:522a. Abstract 2014.
   Google Scholar
• MAUER AM, MASTERS GA, HARAF DJ et al.: Phase I study of docetaxel with concomitant thoracic radiation therapy. Oricol. (1998) 16:159–164.
   PubMed Web of Science ®Google Scholar